April 19, 2022 07:34 AM EDT

Axsome agrees to post-marketing commitments with FDA, signaling potential OK for long-delayed depression drug

Axsome Therapeutics is likely on the cusp of its first drug approval, sending shares of its stock up more than 40% pre-market on Tuesday. …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ax­some agrees to post-mar­ket­ing com­mit­ments with FDA, sig­nal­ing po­ten­tial OK for long-de­layed de­pres­sion drug